Pancreatic cancer |
Regulated by mutant KRAS gene, promoting survival of cancer cells |
Grabocka & Bar‐Sagi, 2016
|
Hepatocellular carcinoma |
Resistance to chemotherapeutic drugs like sorafenib |
Adjibade et al., 2015
|
Glioma/glioblastoma |
Assembly in the eIF2A‐dependent way, promoting survival of cancer cells |
Vilas‐Boas Fde et al., 2016
|
Sarcoma |
YB1 and G3BP1 participating in related biological pathways, associated with the poor prognosis |
Somasekharan et al., 2015
|
Mantle cell myeloma |
Assembly in response to bortezomib while resistant to bortezomib‐induced apoptosis |
Fournier et al., 2010
|
Colorectal cancer |
Induced by 5‐fluorouracil (5‐Fu) or bortezomib in the eIF2A‐dependent way, promoting survival of cancer cells |
Fournier et al., 2010
|
Mazroui et al., 2007
|
Head and neck cancers |
Induced by MG132 or 5‐Fu in the eIF2A‐dependent way, promoting survival of cancer cells |
Mazroui et al., 2007
|
Kaehler et al., 2014
|
Prostate cancer |
Induced by the chemotherapeutic drug sodium selenite in the ROS‐dependent way, promoting cell death instead of cell survival |
Fujimura, Sasaki, & Anderson, 2012
|